Bleeding associated with coadministration of rivaroxaban and clarithromycin

被引：21
作者：
Fralick, Michael [1 ]
Juurlink, David N. [1 ,2 ,3 ]
Marras, Theodore [1 ,4 ]
机构：
[1] Univ Toronto, Dept Med, Toronto, ON, Canada
[2] Inst Clin Evaluat Sci, Toronto, ON, Canada
[3] Sunnybrook Hlth Sci Ctr, Div Internal Med, Toronto, ON M4N 3M5, Canada
[4] Univ Hlth Network, Dept Med, Div Respirol, Toronto, ON, Canada
来源：
CANADIAN MEDICAL ASSOCIATION JOURNAL | 2016年 / 188卷 / 09期
关键词：
D O I：
10.1503/cmaj.150580
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：669 / 672
页数：4
相关论文
共 11 条
[1]   In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban [J].
Gnoth, Mark Jean ;
Buetehorn, Ulf ;
Muenster, Uwe ;
Schwarz, Thomas ;
Sandmann, Steffen .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2011, 338 (01) :372-380
[2]   Systematic overview of warfarin and its drug and food interactions [J].
Holbrook, AM ;
Pereira, JA ;
Labiris, R ;
McDonald, H ;
Douketis, JD ;
Crowther, M ;
Wells, PS .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (10) :1095-1106
[3]   Rivaroxaban and Hemostasis in Emergency Care [J].
Koscielny, Juergen ;
Rutkauskaite, Edita .
EMERGENCY MEDICINE INTERNATIONAL, 2014, 2014
[4]   Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects [J].
Mueck, Wolfgang ;
Kubitza, Dagmar ;
Becka, Michael .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 76 (03) :455-466
[5]   Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism.: Findings from the RIETE Registry [J].
Ruiz-Gimenez, Nuria ;
Suarez, Carmen ;
Gonzalez, Rocio ;
Antonio Nieto, Jose ;
Antonio Todoli, Jose ;
Luis Samperiz, Angel ;
Monreal, Manuel .
THROMBOSIS AND HAEMOSTASIS, 2008, 100 (01) :26-31
[6]   Laboratory assessment of rivaroxaban: A review [J].
Samama M.M. ;
Contant G. ;
Spiro T.E. ;
Perzborn E. ;
Le Flem L. ;
Guinet C. ;
Gourmelin Y. ;
Rohde G. ;
Martinoli J.-L. .
Thrombosis Journal, 11 (1)
[7]   Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls [J].
Samama, Meyer Michel ;
Contant, Genevieve ;
Spiro, Theodore E. ;
Perzborn, Elisabeth ;
Guinet, Celine ;
Gourmelin, Yves ;
Le Flem, Lena ;
Rohde, Gabriele ;
Martinoli, Jean Luc .
THROMBOSIS AND HAEMOSTASIS, 2012, 107 (02) :379-387
[8]   Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity [J].
Siegal, Deborah M. ;
Curnutte, John T. ;
Connolly, Stuart J. ;
Lu, Genmin ;
Conley, Pamela B. ;
Wiens, Brian L. ;
Mathur, Vandana S. ;
Castillo, Janice ;
Bronson, Michele D. ;
Leeds, Janet M. ;
Mar, Florie A. ;
Gold, Alex ;
Crowther, Mark A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (25) :2413-2424
[9]   Effect of clarithromycin on renal excretion of digoxin: Interaction with P-glycoprotein [J].
Wakasugi, H ;
Yano, I ;
Ito, T ;
Hashida, T ;
Futami, T ;
Nohara, R ;
Sasayama, S ;
Inui, K .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (01) :123-128
[10]   Meta-Analysis of Rivaroxaban and Bleeding Risk [J].
Wasserlauf, Guila ;
Grandi, Sonia M. ;
Filion, Kristian B. ;
Eisenberg, Mark J. .
AMERICAN JOURNAL OF CARDIOLOGY, 2013, 112 (03) :454-460
12